• 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 喝了6瓶劲酒和1斤白酒 男子手持钢锯在重庆西站撒泼遭控制 2019-06-01
  • 全世界人民都要顺应人类社会发展规律,不断扩大社会财富公有制的范围,不断缩小社会财富私有制的范围,以便最终消灭社会财富私有制,建立共产主义社会财富公有制。 2019-05-28
  • 先生们,当年潘大也不是一个人。 2019-05-28
  • 开训即开战!新疆万名官兵练兵备战 场面震撼! 2019-05-23
  • 清明五一假期将至 韩国酒店为迎中国游客各出奇招 2019-05-08
  • [大笑]阿Q都是这么说的。。。。。。 2019-05-08
  • 乐清湾跨海大桥雄伟壮观 2019-05-04
  • 湖南省益阳市牵手第十二师二二一团举办“湘疆情深 爱洒兵团”捐赠仪式 2019-05-04
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>新品动态>Gen-Probe获准销售PROGENSA PCA3 Assay

    时时彩刷水稳赚的玩法: Gen-Probe获准销售PROGENSA PCA3 Assay

    Gen-Probe2012年2月16日 19:09 点击:3092

    时时彩网络平台 www.qlgr.net



    FDA批准Gen-Probe公司的PROGENSA® PCA3试剂,第一次尿液为基础的分子测试,以帮助确定需要重复前列腺活检

     

    FDA Approves Gen-Probe's PROGENSA® PCA3 Assay, First Urine-Based Molecular Test to Help Determine Need for Repeat Prostate Biopsies

    -- Test May Help Reduce Unnecessary Repeat Prostate Biopsies --

    SAN DIEGO, Feb. 15, 2012 /PRNewswire/ -- Gen-Probe (NASDAQ: GPRO) announced today the US Food and Drug Administration (FDA) has approved its PROGENSA® PCA3 (Prostate Cancer gene 3) assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.

    To view the multimedia assets associated with this release, please click://www.multivu.com/mnr/53530-gen-probe-progensa-pca3-prostate-cancer-psa

    (Photo:  //photos.prnewswire.com/prnh/20120215/MM40563)

    "When used in conjunction with other diagnostic information, our PROGENSA PCA3 assay provides clinically important information that helps physicians and their patients make better, more informed decisions about one of the most vexing problems in prostate cancer diagnosis," said  Carl Hull, Gen-Probe's Chairman and Chief Executive Officer.  "From a commercial perspective, this is the third of four potential US regulatory approvals that we expect to generate a significant new sales growth cycle for the Company."

    "Over-expression of the PCA3 gene is highly specific to cancerous prostate tissue," said  John Wei, MD, MS, Professor of Urology at the University of Michigan Health System.  "When evaluated with other risk factors, the PROGENSA PCA3 assay fills an important unmet clinical need by helping physicians identify which men suspected of having prostate cancer should undergo a repeat prostate biopsy."

    The PROGENSA PCA3 assay is indicated for use in conjunction with other patient information to aid in the decision for repeat biopsy in men 50 years of age or older who have had one or more previous negative prostate biopsies and for whom a repeat biopsy would be recommended by a urologist based on the current standard of care, before consideration of PROGENSA PCA3 assay results.  A negative PROGENSA PCA3 assay result is associated with a decreased likelihood of a positive biopsy.  A prostate biopsy is required to diagnose cancer.

    Important Safety Information

    The PROGENSA PCA3 assay should not be used for men with atypical small acinar proliferation (ASAP) on their most recent biopsy.  Men with ASAP on their most recent biopsy should be treated in accordance with current medical guidelines.

    The clinical study of the PROGENSA PCA3 assay only included men who were recommended for repeat biopsy.  Therefore, the performance of the assay has not been established in men for whom a repeat biopsy was not already recommended.

    FDA approval of the PROGENSA PCA3 assay was based on a clinical study that began in August 2009 and concluded in May 2010.  The study enrolled 495 eligible men at 14 clinical sites.  Gen-Probesubmitted a Premarket Approval Application (PMA) to the FDA in August 2010.

    In the clinical study, the PROGENSA PCA3 had a negative predictive value of 90%, meaning that a negative PROGENSA PCA3 assay result predicted a negative prostate biopsy 90% of the time.

    About Prostate Cancer and the PROGENSA PCA3 Assay

    According to the American Cancer Society (ACS), prostate cancer is the second most common type of cancer found in American men (behind skin cancer), and the second-leading cause of cancer death in men (after lung cancer).  One in six American men will get prostate cancer during his lifetime, and one in 36 will die from it.  The ACS estimates that about 241,000 Americans were newly diagnosed with prostate cancer in 2011, and that approximately 34,000 men died from the disease.

    PCA3 is a gene that is highly over-expressed in prostate cancers.  Following a digital rectal examination, the PCA3 gene can be quantified in urine specimens together with the prostate-specific antigen (PSA) gene to generate a PCA3 score.  Studies have shown that because the PCA3 gene is highly specific for prostate cancer, it predicts the results of repeat biopsies more accurately than traditional serum PSA testing in patients who have had one or more previous negative prostate biopsies.

    Data from more than 80 peer-reviewed publications suggest that PCA3 gene testing, when used with other patient information, may help address some of the well-known challenges urologists face, such as identifying prostate cancers while reducing unnecessary repeat biopsies.

    Gen-Probe's PROGENSA PCA3 assay is the first urine-based molecular diagnostic assay to aid in the decision for repeat biopsy.  The test has received regulatory approval and is available for sale in the United States, Canada and the European Union.

    Gen-Probe acquired exclusive worldwide diagnostic rights to the PCA3 gene from DiagnoCure (CUR: TO) in November 2003.

    About Gen-Probe

    Gen-Probe is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility. Gen-Probe is headquartered in San Diego and employs approximately 1,400 people.  For more information, go to//www.gen-probe.com.

    Caution Regarding Forward-Looking Statements

    Any statements in this press release about Gen-Probe's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements.  These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would.  For example, statements concerning the development and commercialization of new products, regulatory approvals, customer adoption, and results of future clinical studies are all forward-looking statements.  Forward-looking statements are not guarantees of performance.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied.  Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to: (i) the possibility that the market for the sale of our PROGENSA PCA3 product in the United States or Canada may not develop as expected; (ii) the risk that we may not be able to compete effectively; (iii) the risk that adequate reimbursement will not be available for our PROGENSA PCA3 assay; (iv) the risk that we may not be able to maintain our current corporate collaborations and enter into new corporate collaborations or customer contracts; and (v) the risk that third parties may not distribute our products effectively.  The foregoing describes some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements.  For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports.  We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

    SOURCE Gen-Probe Incorporated

    Michael Watts, Vice president, investor relations and corporate communications, +1-858-410-8673; or Alyssa Eggum, Director, Global MarCom and Branding, Gen-Probe Incorporated, +1-858-410-8647

    (来源: Gen-Probe )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 喝了6瓶劲酒和1斤白酒 男子手持钢锯在重庆西站撒泼遭控制 2019-06-01
  • 全世界人民都要顺应人类社会发展规律,不断扩大社会财富公有制的范围,不断缩小社会财富私有制的范围,以便最终消灭社会财富私有制,建立共产主义社会财富公有制。 2019-05-28
  • 先生们,当年潘大也不是一个人。 2019-05-28
  • 开训即开战!新疆万名官兵练兵备战 场面震撼! 2019-05-23
  • 清明五一假期将至 韩国酒店为迎中国游客各出奇招 2019-05-08
  • [大笑]阿Q都是这么说的。。。。。。 2019-05-08
  • 乐清湾跨海大桥雄伟壮观 2019-05-04
  • 湖南省益阳市牵手第十二师二二一团举办“湘疆情深 爱洒兵团”捐赠仪式 2019-05-04
  • 一波中特诗082期 网上赌场优惠 江西多乐彩十一选五今天开奖的 北京赛车pk10彩票控 腾讯彩票双色球杀号 广东快乐十分开奖直播 竞彩足球比分真播 北京快三走势图预测 新疆11选5彩开奖号码 平特肖研究论坛 球迷家app 天津11选5开奖天津体彩网 内蒙古快3开奖结果昨天 福建十一选五计划 高额德州扑克主题曲